Pfizer’s Sasanlimab Boosts Event-Free Survival in High-Risk NMIBC Pfizer Inc. (NYSE: PFE) announced today significant findings from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody, in combination with the standard of care (SOC) Bacillus Calmette-Guérin…
UGN-102 Trials Show No Impact on Function, Symptoms, or QoL in LG-IR-NMIBC Patients UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on developing and commercializing innovative treatments for urothelial and specialty cancers, announced new data supporting its investigational intravesical…
CytoAgents Completes Cohort 1 Dose-Escalation in Phase 1B Clinical Trial for Cytokine Release Syndrome Research CytoAgents Inc., a clinical-stage biotechnology company at the forefront of developing therapies for immune-mediated disorders, has announced a significant milestone in its ongoing Phase 1b/2a…
Debiopharm and Oncodesign Services Partner to Advance Radiopharmaceuticals in Preclinical Research Debiopharm Research & Manufacturing S.A. (Debiopharm), a privately held, Swiss-based global biopharmaceutical company committed to advancing the treatment landscape for cancer and infectious diseases, has announced a strategic licensing…
Novocure to Present Late-Breaking Phase 3 PANOVA-3 Data for TTFields in Pancreatic Cancer at ASCO 2025 Novocure, a global leader in innovative cancer treatments, has announced that it will present additional data from its pivotal Phase 3 PANOVA-3 trial of…
Zai Lab to Present Phase 1 Data on DLL3-Targeted ADC ZL-1310 at ASCO 2025 Zai Lab Limited , a leading innovative biopharmaceutical company, announced today that it will present updated clinical data from its ongoing global Phase 1a/1b study evaluating…
EditCo Bio and Promega Team Up to Advance Cell-Based Research In a pivotal move set to reshape the landscape of functional genomics and cell engineering, EditCo Bio, Inc. has announced a strategic licensing agreement with Promega Corporation. This collaboration grants…
Metro International Biotech Begins Phase 1a Trial of NAD Booster MIB-725 Metro International Biotech, LLC (MetroBiotech), a pioneering company in the development of next-generation therapies for age-associated diseases, has officially launched its first-in-human clinical trial for MIB-725, a novel investigational…
Feinstein Researchers Lead Breakthrough Study for Lupus Kidney Disease In a significant breakthrough for autoimmune disease treatment, researchers at Northwell Health’s Feinstein Institutes for Medical Research have reported encouraging results from a global Phase 3 clinical trial evaluating the use…
Kairos Pharma Wins DoD Grant to Study ENV105 for Drug-Resistant Lung Cancer Kairos Pharma, Ltd. , a clinical-stage biopharmaceutical company focused on developing novel cancer therapies, has announced a major step forward in its mission to improve outcomes for patients…
Glycomine Raises $115M Series C to Advance GLM101 into Phase 2b Trial for PMM2-CDG Glycomine, Inc., a clinical-stage biotechnology company dedicated to developing life-changing therapies for patients suffering from orphan and underserved diseases, has announced the successful closure of a…
Flatiron Health Partners with Veeva to Advance Oncology Research In a significant development for the digital health and clinical research sectors, Flatiron Health—a pioneer in healthtech focused on transforming clinical research—has announced a new strategic partnership with Veeva Systems, a…